Sponsor terminated study due to unforeseen recruitment circumstances amidst the COVID19 pandemic.

The objective of this study is to assess the effects of ergothioneine at two doses, compared to placebo, on cognition, mood, and sleep in healthy adult men and women.

This will be a placebo-controlled, randomized, double-blind, parallel-arm trial. The study will consist of one screening (visit 1a, week 0), one baseline visit (visit 1b, week 0), and three treatment visits (visits 2, 3, and 4; weeks 4, 8, and 16).

Inclusion Criteria:

• Individuals 55-79 years of age.
• Body mass index (BMI) 18.50-34.99 kg/m2
• Non-smoker defined as no smoking for at least 6 months.
• Willing to limit alcohol and caffeine consumption
• Generally, in good health based on medical history and laboratory assessments
• Agree to avoid consumption of mushrooms and excluded medications/supplements for the duration of the study
• Willing to commit to all study procedures

Exclusion Criteria:

• Consumption of mushrooms more than once per week
• History or presence of a psychiatric or neurologic disease including, but not limited to, epilepsy, cerebrovascular disturbance, traumatic injury, or clinically diagnosed dementia or Alzheimer's disease.
• Scores ≥17 on the Beck Depression Inventory
• History of cardiovascular complications, type 1 or type 2 diabetes mellitus, uncontrolled hypertension, or any other clinically significant disorder
• History of cancer except non-melanoma skin cancer or carcinoma in situ of the cervix within the past 2 years
• Use of any product containing marijuana (THC) and/or cannabidiol (CBD) including oral consumption, inhalation, & other
• Any intolerance to any components of the study products
• Exposure to any non-registered drug product within the past 30 days
• History of drug or alcohol abuse
• Considered unfit for any reason as determined by the principal investigator